PriceTargets.com logo

Aprea Therapeutics - APRE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.50
  • Forecasted Upside: 414.95%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.01 As of 11/20/2024 01:00 AM ET
▼ -0.01 (-0.33%)

This chart shows the closing price for APRE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aprea Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APRE

Analyst Price Target is $15.50
▲ +414.95% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $15.50, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 414.95% upside from the last price of $3.01.

This chart shows the closing price for APRE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Aprea Therapeutics. This rating has held steady since February 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/13/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2024WedbushReiterated RatingOutperform$11.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
3/27/2024WedbushBoost TargetOutperform ➝ Outperform$9.00 ➝ $11.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
11/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/10/2023WedbushReiterated RatingOutperform$9.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
3/10/2023Maxim GroupInitiated CoverageBuy
10/10/2022HC WainwrightReiterated RatingBuy$60.00
7/7/2022WedbushInitiated CoverageOutperform$60.00
3/16/2022Royal Bank of CanadaLower TargetSector Perform$100.00 ➝ $80.00
3/16/2022HC WainwrightLower TargetNeutral$80.00 ➝ $40.00
8/20/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
8/16/2021Berenberg BankDowngradeBuy ➝ Hold$80.00
8/16/2021HC WainwrightLower TargetHold ➝ Neutral$120.00 ➝ $80.00
8/13/2021Royal Bank of CanadaLower TargetSector Perform$120.00 ➝ $100.00
8/12/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$100.00 ➝ $60.00
6/17/2021HC WainwrightReiterated RatingHold$120.00
3/17/2021Royal Bank of CanadaLower TargetSector Perform$200.00 ➝ $160.00
12/29/2020Morgan StanleyLower Target$680.00 ➝ $120.00
12/29/2020HC WainwrightReiterated RatingNeutral$600.00 ➝ $120.00
12/29/2020Royal Bank of CanadaReiterated RatingHold$200.00
12/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$800.00 ➝ $200.00
12/28/2020Robert W. BairdDowngradeOutperform ➝ Neutral
12/16/2020Morgan StanleyLower TargetEqual Weight$780.00 ➝ $680.00
12/16/2020Berenberg BankInitiated CoverageBuy$740.00
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutral
8/12/2020HC WainwrightReiterated RatingHold$600.00
6/22/2020HC WainwrightInitiated CoverageNeutral$600.00
6/11/2020Royal Bank of CanadaReiterated RatingBuy$840.00
4/20/2020Robert W. BairdInitiated CoverageOutperform$900.00
4/15/2020Morgan StanleyBoost TargetEqual Weight$720.00 ➝ $780.00
3/29/2020Royal Bank of CanadaReiterated RatingBuy$840.00
3/27/2020Morgan StanleyBoost TargetHold$460.00 ➝ $720.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aprea Therapeutics logo
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Read More

Today's Range

Now: $3.01
Low: $2.87
High: $3.12

50 Day Range

MA: $3.32
Low: $2.54
High: $4.45

52 Week Range

Now: $3.01
Low: $2.15
High: $8.85

Volume

12,025 shs

Average Volume

20,230 shs

Market Capitalization

$16.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Aprea Therapeutics?

The following sell-side analysts have issued research reports on Aprea Therapeutics in the last twelve months: HC Wainwright, and Wedbush.
View the latest analyst ratings for APRE.

What is the current price target for Aprea Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aprea Therapeutics in the last year. Their average twelve-month price target is $15.50, suggesting a possible upside of 415.0%. HC Wainwright has the highest price target set, predicting APRE will reach $20.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $11.00 for Aprea Therapeutics in the next year.
View the latest price targets for APRE.

What is the current consensus analyst rating for Aprea Therapeutics?

Aprea Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APRE will outperform the market and that investors should add to their positions of Aprea Therapeutics.
View the latest ratings for APRE.

What other companies compete with Aprea Therapeutics?

Other companies that are similar to Aprea Therapeutics include Spero Therapeutics, Aligos Therapeutics, Celularity, Procaps Group and ALX Oncology. Learn More about companies similar to Aprea Therapeutics.

How do I contact Aprea Therapeutics' investor relations team?

Aprea Therapeutics' physical mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company's listed phone number is 617-463-9385 and its investor relations email address is [email protected]. The official website for Aprea Therapeutics is www.aprea.com. Learn More about contacing Aprea Therapeutics investor relations.